Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Eating Disorders

Ketamine for Eating Disorders

6 papers and 4 clinical trials exploring ketamine as a treatment for eating disorders.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication16 million people worldwide.

Eating Disorders

Eating disorders, including anorexia nervosa and bulimia nervosa, affect approximately 16 million individuals globally. The exploration of psychedelics, such as psilocybin and MDMA, as potential treatments for these conditions is a burgeoning field of research, showing promise in alleviating symptoms and improving quality of life.

Full Eating Disorders profile

Academic Research

6 papers
Open Accessmeta

Neuroimaging in psychedelic drug development: Past, present, and future

This review (2023) discusses the emerging field of psychedelic therapy for psychiatric disorders, emphasizing the potential of classic serotonergic psychedelics like psilocybin and LSD and substances like ketamine, MDMA, and ibogaine. It highlights the role of advanced neuroscientific research methods, particularly neuroimaging using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), in advancing the understanding of drug and therapy effects on the brain. The article identifies key knowledge gaps, including the relationship between acute and longer-term effects, the precise characterization of effects at the 5-HT2A receptor, and the impact of these compounds on neuroplasticity, and proposes a roadmap for future research to address these questions through multimodal PET/MRI studies.

Published
September 27, 2023
Journal
Molecular Psychiatry
Authors
Wall, M. B., Harding, R., Zafar, R., Rabiner, E. A., Nutt, D. J., Erritzoe, D.
Paywallindividual

Ketogenic diet and ketamine infusion treatment to target chronic persistent eating disorder psychopathology in anorexia nervosa: a pilot study

In an open‑label pilot of five weight‑restored adults with chronic anorexia nervosa psychopathology, a therapeutic ketogenic diet followed by six ketamine infusions was safe, maintained weight for most participants and produced significant improvements on multiple eating‑disorder measures. The findings suggest this combined TKD‑ketamine approach may ameliorate persistent shape/weight preoccupations by normalising underlying neurobiology, warranting further controlled trials.

Published
August 23, 2022
Journal
Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
Authors
Calabrese, L., Scolnick, B., Zupec-Kania, B., Beckwith, C., Costello, K., Frank, G. K. W.
Open Accessmeta

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

This review (2022) explores the current evidence and future directions for using ketamine to treat eating disorders (EDs). Potential mechanisms of action, the role of psychotherapy and limitations are discussed.

Published
February 11, 2022
Journal
Brain Sciences
Authors
Ragnhildstveit, A., Slayton, M., Jackson, L. K., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., Robison, R.
Open Accessmeta

Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review

This review (2021) explores the use of ketamine to treat Anorexia Nervosa (AN). The ability of ketamine to induce neuroplasticity, neurogenesis and synaptogenesis is discussed in relation to AN. Furthermore, the known antidepressant effects of ketamine may be beneficial to people with AN as depression is often experienced comorbidly.

Published
November 20, 2021
Journal
Nutrients
Authors
Keeler, J. L., Treasure, J., Juruena, M. F., Kan, C., Himmerich, H.
Open Accessmeta

Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

This review (2021, s=30) investigates the use of ketamine for OCD, addiction (SUD), and eating disorders (ED) and finds that glutamatergic neurotransmission dysregulation underlies these domains. In this area, ketamine can be helpful.

Published
July 27, 2021
Journal
Brain Sciences
Authors
Martinotti, G., Pettorruso, M.
Paywallindividual

Ketamine Use for Suicidal Ideation in the General Hospital: Case Report and Short Review

This case report (n=1) describes an anorexic patient who was treated with repeated dose ketamine (0.5mg/kg, 20mg) following a suicide attempt and persevering suicidal ideation (SI). Although the first dose had little effect, the second dose administered 2 weeks after led to a dramatic decrease in depression, hopelessness, and suicidal ideation.

Published
January 1, 2018
Journal
Journal of Psychiatric Practice
Authors
Vulser, H., Vulser, C., Rieutord, M., Passeron, A., Lefebvre, D., Baup, E., Seigneurie, A. S., Thauvin, I., Lemogne, C.

Clinical Trials

4 trials
RecruitingPhase II

Ketamine for the treatment of depression with anorexia nervosa

This randomised, double-blind, placebo-controlled Phase II trial (n=60) will study the feasibility, safety, and acceptability of oral ketamine (60–180 mg, administered twice weekly) as a treatment for adults with long-standing anorexia nervosa and comorbid treatment-resistant depression.

Started
June 12, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
ISRCTN26462355
Enrolling by invitationPhase II

Ketamine Effects on Learning in Eating Disorders (KETTLE)

This open-label, Phase II trial (n=20) will study the effects of a single intravenous (IV) dose of ketamine (35mg/70kg; 0.5 mg/kg over 40 minutes) on cognitive flexibility in adolescents and young adults (ages 16–26) medically hospitalised for anorexia nervosa or atypical anorexia nervosa.

Started
February 7, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06736769
CompletedPhase I

Modified Ketogenic Diet and Ketamine for Anorexia Nervosa

This open-label pilot study (n=5) aims to investigate whether a two-part outpatient procedure, utilising a modified ketogenic diet followed by a series of titrated ketamine infusions, can lead to improvements or remission of chronic anorexia nervosa in adults who have experienced symptoms for at least three years despite undergoing treatment involving at least two different modalities.

Started
April 12, 2021
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT04714541
Not yet recruitingPhase II

Pilot study on the effects of ketamine on mood and eating disorder cognitions in enduring anorexia nervosa

This interventional trial (n=24) investigates the effects of ketamine (26–52 mg/70 kg) on mood and eating-disorder cognitions in enduring anorexia nervosa (AN).

Started
September 2, 2019
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
ACTRN12618001393246p

Explore further

Search all Ketamine papers Search all Eating Disorders trials Full Ketamine profile Full Eating Disorders profile